Tylenol-maker Kenvue Inc. spoke with Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller ...

Kenvue's interim CEO Kirk Perry met Robert F. Kennedy Jr. to try and dissuade him from listing Tylenol as a potential cause ...

财联社9月7日讯（编辑 赵昊） 周五（9月5日），美国科赴公司（ Kenvue Inc. ）股价收跌9.35%报18.62美元，盘中一度跌约17%至17.15美元，为2024年7月以来的最低水平。

对密切关注此事的人而言，华尔街的整体反应揭示了医疗争议在公开市场中的演变规律。虽然舆情风险可能冲击股价，但分析师的精准评估往往能迅速恢复市场理性，甚至在某些情况下催生股价反弹。就目前而言，专业分析机构认为，至少在现阶段，科赴所经历的泰诺风波更像是市场 ...

Kenvue rushed to the defense of Tylenol, but the stock still suffered a record selloff on news that RFK Jr. will release a ...

Kenvue, responding to reports, maintains its stance that there is no causal link between the use of acetaminophen during ...

Beyond oral care, Kenvue is aligning its strategy with the government’s Healthy China 2030 initiative, a national plan to ...

Kenvue Inc.’s shares fell after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy ...

If you have been watching Kenvue (KVUE) lately, there is a good chance the news has caught your attention. A series of ...

当地时间9月5日，多位知情人士透露，美国卫生与公共服务部一份即将发布的报告，可能会首次以官方名义将一种非常常见的美国品牌止痛退烧药与儿童自闭症联系起来。

Investing.com - Evercore ISI 重申了对 Kenvue Inc (NYSE:KVUE) 的"中性"评级和 $25.00 的目标价，尽管近期该公司一款关键产品引发的担忧导致股价波动。根据 InvestingPro ...